Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i>J.-P. Arnault, Caroline Robert|Clinical Cancer Research|2011Cited by 120